Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy

OncoImmunology

Volumn 3, Issue 3, 2014, Pages

  Wei, Huafeng ^a,b,c   Zhao, Likun ^d   Hellstrom, Ingegerd ^e   Hellstrom, Karl Erik ^e   Guo, Yajun ^a,b,c,d  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b LIAOCHENG UNIVERSITY   (China)

^c Shanghai Key Laboratory of Veterinary Science   (China)

^d SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CD137; Co signaling molecules; Immunotherapy; Monoclonal antibody; Ovarian cancer; PD 1

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD150 ANTIGEN; CD40 ANTIGEN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; MONOCLONAL ANTIBODY PD 1; MUCIN 3; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; NONHUMAN; NOTE; OVARY CANCER; REGULATORY T LYMPHOCYTE; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION;

EID: 84902440104     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28248     Document Type: Note

References (10)

1. Mantia-Smaldone GM, Corr B, Chu CS. Immunotherapy in ovarian cancer. Hum Vaccin Immunother 2012; 8:1179-91; PMID:22906947; http://dx.doi.org/10.4161/hv.20738
2. Dai M, Wei H, Yip YY, Feng Q, He K, Popov V, Hellstrom I, Hellstrom KE. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother 2013; 36:248-57; PMID:23603859; http://dx.doi.org/10.1097/CJI.0b013e3182943549
3. Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai M, Hellstrom I, Hellstrom KE, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 2013; 8:e84927; PMID:24367702; http://dx.doi.org/10.1371/journal. pone.0084927
4. Chen DS, Mellman I. Oncology meets immunology:the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j. immuni.2013.07.012
5. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013; 39:61-73; PMID:23890064; http://dx.doi.org/10.1016/j. immuni.2013.07.005
6. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res 2013; 19:997-1008; PMID:23460531; http://dx.doi.org/10.1158/1078-0432.CCR-12-2214
7. Duraiswamy J, Freeman GJ, Coukos G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013; 73:6900-12; PMID:23975756; http://dx.doi. org/10.1158/0008-5472.CAN-13-1550
8. Verbrugge I, Hagekyriakou J, Sharp LL, Galli M, West A, McLaughlin NM, Duret H, Yagita H, Johnstone RW, Smyth MJ, et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012; 72:3163-74; PMID:22570253; http://dx.doi.org/10.1158/0008-5472.CAN-12-0210
9. Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37:508-16; PMID:21074066; http://dx.doi.org/10.1053/j. seminoncol.2010.09.008
10. Lei C, Liu P, Chen B, Mao Y, Engelmann H, Shin Y, Jaffar J, Hellstrom I, Liu J, Hellstrom KE. Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. J Am Chem Soc 2010; 132:6906-7; PMID:20433206; http://dx.doi.org/10.1021/ja102414t